{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:04Z","timestamp":1790636944096,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clp.2024.08.010","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T14:03:25Z","timestamp":1730383405000},"page":"749-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Care of Pregnant Women Living with Human Immunodeficiency Virus"],"prefix":"10.1016","volume":"51","author":[{"given":"Lynda","family":"Stranix-Chibanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahizechukwu C.","family":"Eke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clp.2024.08.010_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.6874","article-title":"Including pregnant and lactating women in clinical research: moving beyond legal liability","author":"Riley","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QAI.0000000000003076","article-title":"Antiretroviral therapy adherence during and postbreastfeeding cessation measured by tenofovir levels in hair","volume":"91","author":"Nematadzira","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.clp.2024.08.010_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/INF.0000000000002290","article-title":"Epidemiology of perinatal HIV transmission in the United States in the era of its elimination","volume":"38","author":"Nesheim","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"S1","key":"10.1016\/j.clp.2024.08.010_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2240","article-title":"Translating clinical pharmacology data in pregnancy to evidence-based guideline recommendations: perspectives from the HIV field","volume":"63","author":"Brooks","year":"2023","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ogc.2022.10.013","article-title":"Antiretrovirals for human immunodeficiency virus treatment and prevention in pregnancy","volume":"50","author":"Brooks","year":"2023","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"S1","key":"10.1016\/j.clp.2024.08.010_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2227","article-title":"Physiologic changes during pregnancy and impact on small-molecule drugs, biologic (monoclonal antibody) disposition, and response","volume":"63","author":"Eke","year":"2023","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.clp.2024.08.010_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cid\/ciz121","article-title":"Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus","volume":"69","author":"Colbers","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0000000000000318","article-title":"Raltegravir pharmacokinetics during pregnancy","volume":"67","author":"Watts","year":"2014","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.clp.2024.08.010_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","article-title":"Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV","volume":"32","author":"Mulligan","year":"2018","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.clp.2024.08.010_bib18","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","article-title":"Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study)","volume":"16","author":"Waitt","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.clp.2024.08.010_bib19","doi-asserted-by":"crossref","first-page":"ciaa006","DOI":"10.1093\/cid\/ciaa006","article-title":"The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus","volume":"26","author":"Bollen","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib20","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003783","article-title":"A\u00a0study of the pharmacokinetics, safety, and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed pregnant women with HIV","volume":"38","author":"Zhang","year":"2024","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.clp.2024.08.010_bib21","author":"Powis"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1293.2011.00965.x","article-title":"Effect of pregnancy on emtricitabine pharmacokinetics","volume":"13","author":"Stek","year":"2012","journal-title":"HIV Med"},{"issue":"2","key":"10.1016\/j.clp.2024.08.010_bib23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1128\/AAC.00370-11","article-title":"Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women","volume":"56","author":"Benaboud","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAD.0000000000002767","article-title":"Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV","volume":"35","author":"Brooks","year":"2021","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/QAI.0000000000002944","article-title":"Pharmacokinetics of tenofovir alafenamide with boosted protease inhibitors in pregnant and postpartum women living with HIV: results from IMPAACT P1026s","volume":"90","author":"Brooks","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/cid\/ciab1010","article-title":"Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with human immunodeficiency virus (HIV): data from the PANNA network","volume":"75","author":"Bukkems","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.clp.2024.08.010_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3851\/IMP3283","article-title":"Efavirenz pharmacokinetics during pregnancy and infant washout","volume":"24","author":"Kreitchmann","year":"2019","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.clp.2024.08.010_bib28","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.clinthera.2020.07.008","article-title":"Pharmacokinetics of efavirenz 600\u00a0mg once daily during pregnancy and post partum in Ghanaian women living with HIV","volume":"42","author":"Lartey","year":"2020","journal-title":"Clin Therapeut"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAI.0000000000000968","article-title":"Pharmacokinetics of rilpivirine in HIV-infected pregnant women","volume":"72","author":"Tran","year":"2016","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40121-017-0184-8","article-title":"Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a phase 3b, multicenter, open-label study","volume":"7","author":"Osiyemi","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clp.2024.08.010_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00239","article-title":"Etravirine pharmacokinetics in HIV-infected pregnant women","volume":"7","author":"Mulligan","year":"2016","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clp.2024.08.010_bib32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40262-022-01127-0","article-title":"Prediction of maternal and fetal doravirine exposure by integrating physiologically based pharmacokinetic modeling and human placenta perfusion experiments","volume":"61","author":"Bukkems","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.clp.2024.08.010_bib33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/QAD.0000000000002163","article-title":"Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint","volume":"33","author":"Boyd","year":"2019","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.clp.2024.08.010_bib34","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/cid\/civ587","article-title":"Maraviroc pharmacokinetics in HIV-1\u2013Infected pregnant women","volume":"61","author":"Colbers","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.aids.0000210609.52836.d1","article-title":"Impact of pregnancy on abacavir pharmacokinetics","volume":"20","author":"Best","year":"2006","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.clp.2024.08.010_bib36","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/QAD.0000000000001046","article-title":"The pharmacokinetics of abacavir 600\u00a0mg once daily in HIV-1-positive pregnant women","volume":"30","author":"Schalkwijk","year":"2016","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.clp.2024.08.010_bib37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/hiv.12252","article-title":"Pharmacokinetics of tenofovir during pregnancy and postpartum: tenofovir pharmacokinetics in pregnancy","volume":"16","author":"Best","year":"2015","journal-title":"HIV Med"},{"issue":"9","key":"10.1016\/j.clp.2024.08.010_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-1293.2011.00927.x","article-title":"Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women: atazanavir in HIV-infected pregnant women","volume":"12","author":"Conradie","year":"2011","journal-title":"HIV Med"},{"issue":"5","key":"10.1016\/j.clp.2024.08.010_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/QAI.0b013e31820fd093","article-title":"Atazanavir pharmacokinetics with and without tenofovir during pregnancy","volume":"56","author":"Mirochnick","year":"2011","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAI.0b013e318289b4d2","article-title":"Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy","volume":"63","author":"Kreitchmann","year":"2013","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clp.2024.08.010_bib41","author":"Rana"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib42","first-page":"585","article-title":"Adherence predictors in pregnant women living with HIV on tenofovir alafenamide and tenofovir disoproxil fumarate","volume":"5","author":"Eke","year":"2022","journal-title":"J\u00a0Pharm Drug Res"},{"key":"10.1016\/j.clp.2024.08.010_bib43","doi-asserted-by":"crossref","first-page":"1056915","DOI":"10.3389\/fpubh.2022.1056915","article-title":"Interventions to improve antiretroviral adherence in HIV-infected pregnant women: a systematic review and meta-analysis","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002859","article-title":"Tenofovir diphosphate in dried blood spots in pregnant and postpartum women with HIV in Kenya: a novel approach to measuring peripartum adherence","volume":"89","author":"Abuogi","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.clp.2024.08.010_bib45","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hiv.13439","article-title":"Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials","volume":"24","author":"Patel","year":"2023","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJMra2212877","article-title":"Antiretroviral therapy and adverse pregnancy outcomes in people living with HIV. Hardin CC","volume":"388","author":"Eke","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.clp.2024.08.010_bib47","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.2023.5076","article-title":"Antiretroviral treatment of HIV\/AIDS during pregnancy","volume":"329","author":"Eke","year":"2023","journal-title":"JAMA"},{"issue":"10281","key":"10.1016\/j.clp.2024.08.010_bib48","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clp.2024.08.010_bib49","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.clp.2024.08.010_bib50","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.clp.2024.08.010_bib51","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3018(20)30038-2","article-title":"Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial","volume":"7","author":"Jo\u00e3o","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.clp.2024.08.010_bib52","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","article-title":"Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial","volume":"7","author":"Kintu","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clp.2024.08.010_bib53","doi-asserted-by":"crossref","unstructured":"Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight GuidelinesKathleen M Rasmussen, Ann L Yaktine, editors. Washington (DC): National Academies Press (US); 2009. The National Academies Collection: Reports funded by National Institutes of Health.PMID: 20669500 Bookshelf ID: NBK32813 DOI: 10.17226\/12584.","DOI":"10.17226\/12584"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib54","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/S1473-3099(22)00687-9","article-title":"Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women","volume":"23","author":"Eke","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.clp.2024.08.010_bib55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa2200600","article-title":"Dolutegravir in pregnancy as compared with current HIV regimens in the United States","volume":"387","author":"Patel","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.clp.2024.08.010_bib56","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.clp.2024.08.010_bib57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.clp.2024.08.010_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11904-007-0020-y","article-title":"Teratogenicity risk of antiretroviral therapy in pregnancy","volume":"4","author":"Heather Watts","year":"2007","journal-title":"Curr HIV AIDS Rep"},{"issue":"6","key":"10.1016\/j.clp.2024.08.010_bib59","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/ciab203","article-title":"Profile of chronic comorbid conditions and obstetrical complications among pregnant women with human immunodeficiency virus and receiving antiretroviral therapy in the United States","volume":"73","author":"Venkatesh","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.clp.2024.08.010_bib60","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14787210.2022.2125868","article-title":"Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV)","volume":"20","author":"Abdul Massih","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.clp.2024.08.010_bib61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11904-022-00641-x","article-title":"Evidence for implementation: management of TB in HIV and pregnancy","volume":"19","author":"Jones","year":"2022","journal-title":"Curr HIV AIDS Rep"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2471\/BLT.20.272559","article-title":"Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa","volume":"99","author":"Cohn","year":"2021","journal-title":"Bull World Health Organ"},{"issue":"11","key":"10.1016\/j.clp.2024.08.010_bib63","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/v15112142","article-title":"Cytomegalovirus infection in pregnancy prevention and treatment options: a systematic review and meta-analysis","volume":"15","author":"Rybak-Krzyszkowska","year":"2023","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.clp.2024.08.010_bib64","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/v13122455","article-title":"Maternal HPV infection: effects on pregnancy outcome","volume":"13","author":"Condrat","year":"2021","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.clp.2024.08.010_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDe2200069","article-title":"Ethical challenges to improving access to human papillomavirus vaccines in low- and middle-income countries","volume":"1","author":"Eke","year":"2022","journal-title":"NEJM Evid"},{"issue":"14","key":"10.1016\/j.clp.2024.08.010_bib66","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","article-title":"Isoniazid preventive therapy in HIV-infected pregnant and postpartum women","volume":"381","author":"Gupta","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib68","doi-asserted-by":"crossref","DOI":"10.3201\/eid3004.231726","article-title":"Prioritizing mental health within HIV and tuberculosis services in PEPFAR","volume":"30","author":"Fukunaga","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib69","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12888-019-2321-2","article-title":"Prevalence of perinatal depression among HIV-positive women: a systematic review and meta-analysis","volume":"19","author":"Zhu","year":"2019","journal-title":"BMC Psychiatr"},{"issue":"1","key":"10.1016\/j.clp.2024.08.010_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M14-0293","article-title":"Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data","volume":"161","author":"Mollan","year":"2014","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.clp.2024.08.010_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/sextrans-2020-054821","article-title":"Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir\/rilpivirine: a meta-analysis","volume":"97","author":"Allen Reeves","year":"2021","journal-title":"Sex Transm Infect"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510824000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510824000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:33:02Z","timestamp":1730392382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510824000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0095510824000800"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2024.08.010","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Care of Pregnant Women Living with Human Immunodeficiency Virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2024.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}